Search

Search Results

• 

  25 | A phase II, open-label study to improve compliance and time of treatment after obtaining complete response through a tailored schedule of sonidegib in locally advanced basal cell carcinomas – the SONIBEC trial Monica Variolo^1|2, Carlo Resteghini^1|2, Sara Farinatti^1|2, Andrea Alberti³, Valeria Tovazzi³, Paola Queirolo⁴, Maristella Saponara⁴, Giuseppe Argenziano⁵, Riccardo Marconcini⁶, Ketty Peris⁷, Paola Savoia⁸, Maria Chiara Tronconi¹, Iris Zalaudek⁹, Paolo Ascierto¹⁰, Francesco Spagnolo¹¹, Luigi Lorini¹, Cristina Gurizzan¹, Paolo Bossi^1|2 | ¹Medical Oncology and Haematology Unit, IRCCS Humanitas Research Hospital, Rozzano ^MI; ²Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan; ³Medical Oncology Unit, ASST Spedali Civili, Brescia; ⁴Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan; ⁵Unit of Dermatology, Luigi Vanvitelli University of Campania, Naples; ⁶Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa; ⁷Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome; ⁸Department of Health Sciences, University of Eastern Piedmont, Novara; ⁹Department of Dermatology and Venereology, University of Trieste, Ospedale Maggiore, Trieste; ¹⁰Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; ¹¹Department of Medical Oncology, IRCCS AOU San Martino-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.

  Italian Melanoma Intergroup

  11-12-2025

  https://doi.org/10.4081/dr.2025.10767

  320
• 

  34 | Dissecting the spectrum of rare BRAF mutations in melanoma: a nation-wide study by the Italian Melanoma Intergroup Francesco Spagnolo^1|2, Bruna Dalmasso³, Maria Chiara Scaini⁴, Laura Cendron⁵, Monica Rodolfo⁶, Ilaria Mattavelli⁷, Elena Tamborini⁸, Francesca Collina⁹, Gerardo Ferrara, Gabriele Madonna¹⁰, Carlo Cota¹¹, Elisa Melucci¹², Stefania Tommasi¹³, Martina Ubaldi¹⁴, Roberta Depenni¹⁵, Andrea Carugno¹⁶, Riccardo Marconcini¹⁷, Laura Orgiano¹⁸, Maurizio Lombardo¹⁹, Simona Sola²⁰, Cristina Pellegrini²¹, Francesca Castiglione²², Matteo Gasparotto^5|23, Alireza Jorkesh⁵, Stefania Pellegrini⁴, Edoardo Raposio¹, Andrea Boutros², Enrica Teresa Tanda², Michele Guida²⁵, Pietro Quaglino²⁶, Giuseppe Palmieri²⁷, Daniela Massi²², Paolo Antonio Ascierto¹⁰, Mario Mandalà*²⁸, Chiara Menin*⁴, Paola Ghiorzo*²⁴, Lorenza Pastorino*²⁴, for the Italian Melanoma Intergroup²⁹ | ¹Department of Surgical Sciences and Integrated Diagnostics, DISC, Plastic Surgery Division, University of Genoa; ²IRCCS Ospedale Policlinico San Martino, Genova; ³IRCCS Ospedale Policlinico San Martino, Cancer Genetics, Genoa; ⁴Immunology and Molecular Oncology Unit, Veneto Institute of Oncology - IOV IRCCS, Padua; ⁵Department of Biology, University of Padua, Padua; ⁶Unit of Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; ⁷Melanoma Surgical Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; ⁸Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; ⁹Pathology Unit, Istituto Nazionale Tumori, IRCCS - Fondazione G. Pascale, Napoli; ¹⁰Melanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli; ¹¹Dermatopathology Unit, San Gallicano Dermatological Institute IRCCS, Rome; ¹²Pathology Unit, IRCCS Regina Elena, National Cancer Institute, Rome; ¹³Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari; ¹⁴Unit of Medical Oncology, University of Perugia; ¹⁵Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena; ¹⁶Department of Medicine and Surgery, University of Insubria, Varese; ¹⁷Medical Oncology Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa; ¹⁸Department of Medical Oncology, University of Cagliari, Cagliari; ¹⁹Division of Dermatology, Department of Medicine and Surgery, Ospedale di Circolo e Fondazione Macchi, ASST dei Sette Laghi, Varese; ²⁰Surgical Pathology, Galliera Hospital, Genoa; ²¹Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila; ²²Histopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy and Section of Pathology, Department of Health Sciences, University of Florence, Italy; ²³Department of Translational Brain Research, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. ²⁴Department of Internal Medicine and Medical Specialties, University of Genoa; ²⁵Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari; ²⁶Dermatology Clinic, Department of Medical Sciences, University of Turin; ²⁷Immuno-Oncology & Targeted Cancer Biotherapies, University of Sassari - Unit of Cancer Genetics, IRGB-CNR, Sassari; ²⁸University of Perugia, Medical Oncology Unit, Santa Maria Misericordia Hospital, Perugia; ²⁹Italian Melanoma Intergroup, IMI, Italy. *These authors equally contributed to this work.

  Italian Melanoma Intergroup

  11-12-2025

  https://doi.org/10.4081/dr.2025.10776

  320
• 

  23 | Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: an international retrospective study Maria Chiara Sergi*¹, Teresa Amaral*², Piotr Rutkowski*³, Marie-Lena Rasch², Naima Benannoune⁴, Patricio Serra⁵, Maria Grazia Vitale⁶, Diana Giannarelli⁷, Ana Maria Arance⁸, Eva Munoz Couselo⁹, Bart Neyns¹⁰, Iris Dirven¹¹, Marco Tucci¹², Michele Guida¹³, Francesco Spagnolo¹⁴, Ernesto Rossi¹⁵, Paola Queirolo¹⁶, Pietro Quaglino¹⁷, Roberta Depenni¹⁸, Joanna Placzke³, Anna Maria Di Giacomo¹⁹, Michele Del Vecchio²⁰, Alice Indini²⁰, Ines Pires da Silva²¹, Alexander M. Menzies²², Angela Hong²³, Paul Lorigan⁵, Caroline Robert²⁴, Georgina V. Long²², Paolo A. Ascierto⁶, Mario Mandalà²⁵ | ¹Unit of Medical Oncology, "Mons. A.R. Dimiccoli" Hospital, Asl BT, Barletta, Italy; ²Skin Cancer Clinical Trials Center, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany. ³Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. ⁴Gustave Roussy Cancer Campus, Villejuif, France. ⁵The University of Manchester, Manchester, UK. ⁶Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, I.N.T. IRCCS Fondazione "G. Pascale" Napoli, Naples, Italy; ⁷Epidemiology and Biostatistics, Fondazione Policlinico Universitario, A. Gemelli IRCCS, Rome, Italy; ⁸Hospital Clínic Barcelona and IDIBAPS, Barcelona, Spain; ⁹Department of medical oncology. Vall d"Hebron Hospital, Barcelona, Spain & Vall d’Hebron Institute of oncology, VHIO. Barcelona, Spain; ¹⁰Department of Medical Oncology, UZ Brussel, Brussels, Belgium. ¹¹Department of medical oncology, Vrije Universiteit Brussel, VUB, Universitair Ziekenhuis Brussel, Brussels, Belgium; ¹²Medical Oncology Unit, University of Bari Aldo Moro, Policlinico Hospital of Bari, 70124 Bari, Italy. ¹³Rare Tumors and Melanoma Unit, IRCCS Istituto dei Tumori "Giovanni Paolo II," Bari, Italy. ¹⁴IRCCS Ospedale Policlinico San Martino, Skin Cancer Unit, Genova, Italy; ¹⁵Medical Oncology, Fondazione Policlinico Universitario, A. Gemelli IRCCS, Rome, Italy; ¹⁶IEO European Institute of Oncology, IRCCS, Milan, Italy. ¹⁷Department of Dermatology, University of Turin, Turin, Italy. ¹⁸University of Modena and Reggio Emilia, Department of Oncology, Hematology, Modena, Emilia-Romagna, Italy; ¹⁹Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy. ²⁰Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ²¹Melanoma Institute Australia, University of Sydney, and Blacktown Hospital, Sydney, New South Wales, Australia; ²²Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia; ²³Faculty of Medicine and Health, Sydney Medical School, The University of Sydney, Australia; Department of Radiation Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australia; ²⁴Gustave Roussy and Paris-Saclay University, Villejuif, France; ²⁵Unit of Medical Oncology, University of Perugia, Perugia, Italy. ^§ on behalf of the Italian Melanoma Intergroup - IMI.

  Italian Melanoma Intergroup

  11-12-2025

  https://doi.org/10.4081/dr.2025.10765

  292
• 

  28 | Efficacy and toxicity outcomes with doublet immunotherapy in metastatic melanoma: the real-world REALIPINIVO study Miriam Forte¹, Francesco Caraglia¹, Silvana Cozzolino¹, Antonino Colloca¹, Alfonso Esposito¹, Maria Cristina Giugliano¹, Eleonora Cioli¹, Marcella Scala², Francesca Sparano⁵, Maria Chiara Sergi³, Teresa Del Giudice⁴, Immacolata Paciolla⁶, Luigi Formisano², Stefania Napolitano¹, Antonio Maria Grimaldi⁶, Paolo Antonio Ascierto⁵, Fortunato Ciardiello¹, Teresa Troiani¹, Vincenzo De Falco¹ | ¹Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples; ²Department of Clinical Medicine and Surgery, Federico Il University, Naples; ³Unità Operativa Complessa di Oncologia Medica, Ospedale "Mons. A.R. Dimiccoli", Barletta; ⁴Nuclear Medicine Unit, "Mater Domini" University Hospital, Catanzaro; ⁵Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Napoli; ⁶Medical Oncology Unit AORN "San Pio", Benevento, Italy.

  Italian Melanoma Intergroup

  11-12-2025

  https://doi.org/10.4081/dr.2025.10770

  335
• 

  27 | Real-world data for malignant melanoma stage II adjuvant therapy Silvana Cozzolino¹, Antonino Colloca¹, Miriam Forte¹, Francesco Caraglia¹, Alfonso Esposito¹, Maria Cristina Giugliano¹, Eleonora Cioli¹, Marcella Scala², Maria Chiara Sergi³, Teresa Del Giudice⁴, Francesca Sparano⁵, Immacolata Paciolla⁶, Mariangela Pasqualoni⁷, Luigi Formisano², Stefania Napolitano¹, Antonio Maria Grimaldi¹, Paolo Antonio Ascierto⁵, Fortunato Ciardiello¹, Teresa Troiani¹, Vincenzo De Falco¹ | ¹Medical Oncology, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples; ²Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy; ³Division of Medical Oncology, "Mons. A.R. Dimiccoli" Hospital, Barletta; ⁴Nuclear Medicine Unit, "Mater Domini" University Hospital, Catanzaro; ⁵Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples; ⁶Medical Oncology Unit, AORN "San Pio", Benevento, Italy; ⁷Medical Oncology Unit, ASL Taranto, Italy.

  Italian Melanoma Intergroup

  11-12-2025

  https://doi.org/10.4081/dr.2025.10769

  336